First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. - Wikidata - awgldk - TriplyDB

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

http://www.wikidata.org/entity/Q46610982

about

Evolutionary dynamics of cancer in response to targeted combination therapy Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer Irreversible EGFR-TKIs: dreaming perfection Nanomedicine therapeutic approaches to overcome cancer drug resistance Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer Molecular pathology of lung cancer: key to personalized medicine.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Detection of mutations in EGFR in circulating lung-cancer cells Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches.Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).Performance evaluation of indel calling tools using real short-read data Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.

P2860

Q21128788-045D8E23-6E5F-445D-B74D-F00A5397BE02 Q21144211-C608BAA2-FE35-4177-8B9C-A5744307D793 Q21198843-01A647C5-DC6C-4B01-A727-2EB3B3421797 Q24600031-7907D014-798E-4D7B-BE40-F703113F3442 Q24625201-A5C6BE33-D30B-4818-B05D-7AD77C89165A Q26739096-844473B4-9D7D-4BDB-A2C1-94A8686DCA6F Q26744339-8C03AE91-B021-4137-AFAD-922F42BFD838 Q26768125-FEBA2B37-0886-4A76-B5AD-4D2993A7A6A1 Q26771116-1833B709-C873-4EB9-87F2-CDF0C69A005D Q26797297-217BF904-EC8F-4A66-9102-8F123494DFCE Q26823305-E6BDD2AB-48FB-4503-A289-CE0ECC219AC0 Q26828860-D1FF6AE2-CD6B-4251-B694-E1104AC091B8 Q26865779-75BBB182-BF63-467A-BF30-569EDB4B2C8E Q26866186-10D58290-E1B3-48AE-A380-C60855723861 Q27011692-029B8456-F09D-4F86-9205-7AFC12A01620 Q27014117-7E28E0E4-AEE3-4DC1-A044-EE6ECED9A797 Q27015224-48963578-2847-4F33-9426-B3D1F160E72F Q27021738-F2D94C5C-C6D9-489D-9C5C-43B1EAE57231 Q27317429-2CA7C054-C33F-4857-BBD8-58A612FE77D7 Q27680966-FC95F6FC-CEB8-4FC7-8A8C-C349DAB8BFDD Q27691299-6999B2A5-30A5-4583-8A45-5F3F2B4479E3 Q27851588-39D5C136-FD5D-4A0D-A89A-CF82BFFC9807 Q27851628-3A6D9547-10A3-452A-BA8B-8F76CBAAE9BC Q27851633-6FFF8D4B-7677-4A4F-BF59-6CBBFF8CA107 Q27851660-ED41324E-ACEA-4BBD-B6B8-6D660C058186 Q27853013-1CFEB07C-00BB-4A7B-903F-C571B38BC048 Q27853182-ABF56B64-C687-44EC-AC19-BA6971504880 Q28069900-A2E6FF43-914A-4E74-B836-D1E66C7C0EF4 Q28077340-8ACCACCB-7CED-4982-8EF4-ED60F33AD949 Q28083239-07C4B546-A5C4-45A0-B085-230AA2518E3A Q28303718-CAE7D0B2-3480-4A06-A046-D1CE1D4D1944 Q28544732-821B0C5D-091B-4BBE-9280-3F9EC87898D2 Q28603408-E54EA70E-3A43-48AF-875A-6AEDDCAB76F1 Q29615033-9C1EFE19-309A-46DA-93E6-434D97A56687 Q29615472-7DE8E646-62AD-44F2-BB57-6D9DE38FAF2F Q30279226-D721A684-19AA-45CC-BC5F-94994D7F56C0 Q30729747-E30A3124-D94B-4E4D-8AE1-D644369F0298 Q30932996-383506AE-5211-4AD3-A48D-20AF625FFEC7 Q30988060-A08448D8-6453-488A-A1A0-FBDE9CA6B8C5 Q33438894-D56AB2C2-99EC-40B5-9A33-5F96D2BD4658

P2860

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

http://www.wikidata.org/entity/Q46610982

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@en

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@nl

type

label

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@en

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@nl

prefLabel

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@en

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@nl

P1433

Q46610982-D90C32FC-3DD2-4B26-B92D-1376F61A053B

P1476

Q46610982-B56739C4-0B93-4CED-9502-FF6DE1A43492

P2093

Q46610982-07ECD915-2F5C-4DA4-893B-8D09B15ED6E3

Q46610982-2307A22B-061E-44E0-89E2-0EB93C029B58

Q46610982-2CA4BD89-3142-4FE4-A020-BDFA88B0A9A5

Q46610982-334B1130-0B09-4789-9A4A-5A368BE4C9D7

Q46610982-37D8FA68-26BE-422F-82F1-3F09696308BB

Q46610982-3EF431EC-0DC9-46D7-8F22-5E5FD26E5487

Q46610982-59A64239-0AAB-43C7-BC9D-D443F43F5C03

Q46610982-7105FE50-1064-4EDB-BF26-BDD10F62EFF6

Q46610982-73B8AD4B-191C-4699-B5F8-35B4060054CD

Q46610982-77B99857-3367-4FC2-BC09-58C7D94035FF

P304

Q46610982-C8FB2F5B-F92F-4D06-9A9E-52A6ACD8EE56

P31

Q46610982-07DD2C02-ACE1-421A-8754-D75715004594

P356

Q46610982-161BCC7E-AB5C-42B2-AE8A-BBE26FE9B3D5

P407

Q46610982-38128F9F-7020-4A6E-8541-630F6B71E30F

P433

Q46610982-1D57F64F-506C-48AB-9EF5-CE31C10E9DBF

P478

Q46610982-868B2918-E998-4BBC-80EF-EF4B2A9BF7FF

P50

Q46610982-BB643057-94AB-4D9A-872B-DA07E2F2310F

P577

Q46610982-BCDD173B-C197-4F06-810F-432A3B6E87E1

P698

Q46610982-9B21B2FC-9F35-481C-9B6E-9231226CBA78

P356

JCO.2007.14.8494

P1433

Journal of Clinical Oncology

P1476

First-line gefitinib in patien ...... boring somatic EGFR mutations.

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Alexander Spira

http://www.w3.org/2001/XMLSchema#string

Alona Muzikansky

http://www.w3.org/2001/XMLSchema#string

Bruce E Johnson

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

David McCollum

http://www.w3.org/2001/XMLSchema#string

David Spigel

http://www.w3.org/2001/XMLSchema#string

Georgiana L Kuhlmann

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Jeffrey Settleman

http://www.w3.org/2001/XMLSchema#string

P304

2442-2449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.8494

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18458038

http://www.w3.org/2001/XMLSchema#string